Fresh analysis suggests that people who come off new GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who stop traditional lifestyle programs.
Research printed in a major health publication demonstrates that while overweight individuals frequently drop substantial amounts of their total mass while on the medication, the mass returns at an average rate of 0.8 kg per month after stopping.
"Users purchasing these treatments need to be cognizant of the danger of quick rebound weight gain when the medication ends," stated expert Dr. Susan Jebb.
This pace of regain suggests a reversion to starting weight within about 18 months.
Weighing Therapies
The research, which looked at dozens of trials involving over 9,000 of participants, compared the effects of the injectable medications with older methods.
Researchers emphasize that individuals who lose weight through dieting generally see a slower weight regain—around 0.1 kg a month—post-intervention.
Understanding the Quick Regain
Doctors propose the mechanism of the injections is key to understanding the amplified rebound.
These medications imitate a natural hormone called GLP-1, which controls hunger.
"Artificially providing GLP-1 concentrations far above than normal might result in the body to generate a reduced amount of its endogenous hormone, and could reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' results in appetite is uncontrolled, making binge eating much more probable."
A Chronic Issue?
The NHS recommend the jabs for people with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Professionals contend that, due to the high risk of weight regain, the treatment should be considered ongoing.
This opinion is echoed by drug manufacturers, who say that the results "underscore the long-term character of obesity," similar to managing conditions like hypertension.
User Testimonies
Individuals who have come off the medication report a intense return of appetite.
"It felt as if something activating and you're instantly ravenous," said one woman.
This challenge is exacerbated if patients have not developed lasting lifestyle or habit modifications during therapy.
Significant Adoption
Figures show that millions of adults in the UK have used these injections in the past year, with demand remaining high.
- Adoption is higher among females than males.
- The 40s and 50s age group shows the greatest level of interest.
- A large proportion obtain the medications through private prescriptions rather than public health services.
Finally, researchers stress that while the jabs are potent agents for weight loss, they are not a magic fix and maintained weight loss hinges on ongoing behavioural support.
